Astellas Pharma Inc (ALPMY)
9.85
-0.23
(-2.28%)
USD |
OTCM |
Dec 16, 16:00
Astellas Pharma Enterprise Value: 22.23B for Dec. 13, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 71.58B |
| Pfizer Inc | 201.90B |
| Nxera Pharma Co Ltd | 719.79M |
| PeptiDream Inc | 2.195B |
| Healios KK | 104.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 241.22M |
| Revenue (Quarterly) | 3.035B |
| Total Expenses (Quarterly) | 2.728B |
| EPS Diluted (Quarterly) | 0.1343 |
| Gross Profit Margin (Quarterly) | 80.74% |
| Profit Margin (Quarterly) | 7.95% |
| Earnings Yield | 0.59% |
| Operating Earnings Yield | 0.58% |
| Normalized Earnings Yield | 0.2767 |